文献速递糖尿病

儿童糖尿病队列中常规大规模平行测序筛查MODY的成本效果分析

Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life.
PubMed 文献 · Diabetes Care · 2018-12-06

该研究基于澳大利亚儿童糖尿病队列,构建30年Markov模型,比较常规大规模平行测序筛查MODY与标准实践的成本效果。结果显示常规MPS筛查更具成本效果,每1000例患者可获得26个QALY并节省1,016,000澳元,筛查成本在10年内完全抵消。

要点

  • 常规MPS筛查MODY比标准实践更有效且更省钱
  • 每1000例患者可多获得26个QALY并节省1,016,000澳元
  • 筛查成本在10年内完全抵消,MODY患病率降至<1.1%前均占优

核心结论

  • 在儿童糖尿病队列中,常规MPS筛查MODY可降低卫生系统成本并改善患者生活质量。

研究设计与样本

  • 基于澳大利亚儿童糖尿病队列的观察数据,构建Markov决策模型,模拟30年增量成本和QALY,比较常规MPS筛查与标准实践。

主要发现

  • 常规MPS筛查MODY比标准实践筛查更有效且成本更低,每1000例患者获得26个QALY并节省1,016,000澳元(782,000美元)。
  • 筛查成本在10年内完全抵消。
  • 只要MODY患病率不低于1.1%,常规MPS筛查始终占优。

关键数值与推荐

  • 模型采用观察到的MODY患病率2.14%,标准实践基于已发表数据的0.7%。
  • 长期糖尿病并发症的概率和效用权重基于HbA1c并从已发表数据估算。

临床怎么用

  • 结果支持对所有疑似1型糖尿病的儿童进行常规基因筛查以识别MODY。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Maturity-onset diabetes of the young (MODY) is an autosomal dominant form of diabetes, with multiple causative genes. Some MODY subtypes can be treated with sulfonylureas instead of insulin, improving glycemic control, complication rates, quality of life (QoL), and costs. Using massively parallel sequencing (MPS), we recently determined the prevalence of pathogenic/likely pathogenic MODY variants in an Australian pediatric diabetes cohort. Here, these data are used to estimate cost-effectiveness of using MPS for MODY in all pediatric diabetes cases compared with standard practice (sequencing limited to individuals with specific clinical features). RESEARCH DESIGN AND METHODS: A Markov decision model was developed to estimate incremental costs and quality-adjusted life-years (QALYs) of MPS screening, modeled over 30 years. We used our observed prevalence of 2.14% compared with 0.7% for standard practice, based on published data. The probabilities and utility weightings of long-term diabetes complications were based on HbA1c and estimated from published data. A series of one-way sensitivity analyses were performed using the net monetary benefit framework. RESULTS: Routine MPS screening for MODY was more effective and less costly than standard care screening, with 26 QALYs gained and 1,016,000 AUD (782,000 USD) saved per 1,000 patients. Cost of screening was fully offset within 10 years. Routine MPS screening remained dominant until MODY prevalence fell to <1.1%. CONCLUSIONS: Routine MPS screening for MODY in the pediatric population with diabetes could reduce health system costs and improve patient QoL. Our results make a compelling argument for routine genetic screening in all children with presumed type 1 diabetes mellitus.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Johnson SR, Carter HE, Leo P, et al. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. Diabetes Care. 2018. PMID: 30523035. doi:10.2337/dc18-0261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。